Abstracts tagged "proteomics"

Abstract Number: 0816 • ACR Convergence 2024
Distinct Transcript and Protein Dysregulation Patterns in Dermatomyositis and Systemic Lupus Erythematosus
James Ward¹, Mythri Ambatipudi², Zerai Manna³, Michael Smith⁴, Melissa de los Reyes⁵, Adam Schiffenbauer⁶, Saifur Rahman⁷, Kamelia Zerrouki⁵, Fredrick Miller¹, Mariana Kaplan⁸, Jian-Liang Li¹, Kerry Casey⁹, Lisa Rider¹⁰ and Sarfaraz Hasni⁶, ¹National Institute of Environmental Health Sciences, NIH, Durham, NC, ²Harvard Medical School, Boston, MA, ³NIH, Bethesda, MD, ⁴Horizon Therapeutics, Alexandria, VA, ⁵AstraZeneca, Gaithersburg, MD, ⁶NATIONAL INSTITUTES OF HEALTH, Bethesda, MD, ⁷AstraZeneca, Gaithersburg, ⁸NIAMS/NIH, Bethesda, MD, ⁹Regeneron Pharmaceuticals, Terrytown, NY, ¹⁰NIEHS, NIH, Garrett Park, MD
Background/Purpose: Systemic lupus erythematosus (SLE) and dermatomyositis (DM) are hypothesized to be triggered by shared genetic and environmental factors leading to aberrant activation of innate…
Abstract Number: 1711 • ACR Convergence 2024
Identification of Psoriatic Arthritis-related Pathways Using Multi-omics Data Integration
Sreemoyee Ghosh¹, Chiara Pastrello², Omar F. Cruz-Correa³, Darshini Ganatra⁴, Katerina Oikonomopoulou³, Melanie Anderson⁵, Igor Jurisica⁶ and Vinod Chandran⁷, ¹Institute of Medical Science, University of Toronto and Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵The Institute for Education Research, Library and Information Services, University Health Network, Toronto, ON, Canada, ⁶Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, Toronto, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriasis (Pso) is a chronic immune mediated inflammatory skin disease. Up to 24% of Pso patients develop psoriatic arthritis (PsA). Pathophysiology of PsA is…
Abstract Number: 0831 • ACR Convergence 2024
JDM Proteomic Signature at Disease Onset and Progression Highlights Persistent Dysregulation of Cell Death, Redox and Innate Immune Signaling
Jessica Neely¹, Jeff Dvergsten², Zilan Zheng¹, Chioma Madubata³, Hanna Kim⁴, Sara Sabbagh⁵, Sophia Matossian⁶, Christine Goudsmit⁶, Celine Berthier⁶ and Jessica Turnier⁷, and for the CARRA Registry Investigators and Translational Medicine for Juvenile Myositis Working Group, ¹UCSF, San Francisco, CA, ²Duke University Hospital, Hillsborough, NC, ³University of California, San Francisco, San Francisco, CA, ⁴National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵Medical College of Wisconsin, Milwaukee, WI, ⁶University of Michigan, Ann Arbor, MI, ⁷University of Michigan, Saline, MI
Background/Purpose: Juvenile dermatomyositis (JDM) patients frequently have incomplete response to therapy. We utilized exploratory proteomics to advance understanding of dysregulated proteins and biological pathways that…
Abstract Number: 1777 • ACR Convergence 2024
Broad Proteomic Analysis Reveals Top Differential Protein Modules and Functional Annotations with Clinical Traits in Juvenile Dermatomyositis (JDM) and Myositis-Specific Autoantibody (MSA) Groups
Amy Kaneshiro¹, Adeline Chin¹, Lisa Rider², Frederick Miller³, Foo Cheung⁴, Megan Darrell¹, Angelique Biancotto⁴, Ujana Zajmi¹ and Hanna Kim⁵, ¹NIH/NIAMS, Bethesda, MD, ²NIEHS, NIH, Garrett Park, MD, ³NIH, NIEHS, Chapel Hill, NC, ⁴NIH/NIAID, Bethesda, MD, ⁵National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: JDM is a heterogenous systemic autoimmune disease with muscle and skin pathology, which can be clinically subgrouped by MSAs (ex: anti-TIF1, anti-MDA5 autoantibodies (Ab)).…
Abstract Number: 0886 • ACR Convergence 2024
A Longitudinal Cohort Study Uncovers Plasma Protein Biomarkers Predating Clinical Onset and Treatment Response of Rheumatoid Arthritis
Chenxi Zhu¹, Siyu He², Yi Liu³, Rui Sun¹ and Yi Zhao⁴, ¹Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, chengdu, China (People's Republic), ²West China Hospital Sichuan University, chengdu, China (People's Republic), ³Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, chengdu, ⁴Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, Sichuan, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is a complex systemic inflammatory autoimmune disease with a high incidence, primarily affecting the joints. However, it currently lacks definitive biomarkers…
Abstract Number: 1781 • ACR Convergence 2024
Tear Proteomics as a Classifier of Disease Type and Activity Status in Pediatric Uveitis
Melissa Lerman¹, Devlin Eckardt¹, Stefanie Davidson² and Edward Behrens³, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania/CHOP, Philadelphia, PA, ³Children's Hospital of Philadelphia, West Chester, PA
Background/Purpose: Measurement of proteins from tear fluid represents a non-invasive means to assess the local biology of ocular autoimmune disease such as uveitis. Pediatric uveitis…
Abstract Number: 0939 • ACR Convergence 2023
HRCT-derived Delta Radiomic Features Classify Response to Anti-Fibrotic Treatment in Experimental and Human Fibrosing Interstitial Lung Disease
David Lauer¹, Luca Romano Kolly¹, Hubert Gabrys², Matthias Brunner¹, Malgorzata Anna Maciukiewicz¹, Thomas Frauenfelder³, Stephanie Tanadini-Lang², Anne-Christine Uldry⁴, Manfred Heller⁴, Kerstin Klein⁵, Oliver Distler⁶, Janine Gote-Schniering¹ and Britta Maurer⁷, ¹University Hospital Bern, Bern, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁴University of Bern, Bern, Switzerland, ⁵Department of Rheumatology and Immunology, University Hospital Bern, Bern, Switzerland, ⁶Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁷University Hospital Bern, University Bern, Bern, Switzerland
Background/Purpose: Quantification of response to anti-fibrotic drugs in patients with fibrosing interstitial lung disease (ILD) relies on repeated pulmonary function tests (PFT) and visual evaluation…
Abstract Number: 2495 • ACR Convergence 2023
Unbiased Proteomic Approach to Identify Novel Biomarkers of Disease Activity in ANCA- Associated Vasculitis
Natalie Atallah¹, Vahe Panossian², Xiaoqing Fu¹, Claire Cook¹ and Zachary Wallace³, ¹Massachusetts General Hospital, Boston, MA, ²American University of Beirut, Beirut, Lebanon, ³Massachusetts General Hospital, Newton, MA
Background/Purpose: Identifying novel biomarkers of disease activity could improve outcomes by facilitating personalized approaches to treatment decisions in ANCA-associated vasculitis. Biomarkers of disease activity used…
Abstract Number: 0946 • ACR Convergence 2023
Immunoglobulins G Purified from Systemic Sclerosis Patients Influence Cytoplasmic and Nuclear Proteins Profile in Dermal Fibroblasts
Aurélien Chepy¹, Marie Duhamel², Solange Vivier¹, Clément Chauvet¹, Lucile Guilbert³, Eric Hachulla⁴, Sylvain Dubucquoi¹, David Launay¹, Michel Salzet² and Vincent Sobanski¹, ¹Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France, ²Univ. Lille, Inserm, CHU Lille, U1192 - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, Lille, France, ³CHU Lille, Institut d’Immunologie, Lille, France, ⁴CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France
Background/Purpose: Autoantibodies (Aab) are frequent in systemic sclerosis (SSc). While recognized as potent biomarkers, their pathogenic role is unclear. Recently, we showed that immunoglobulins G…
Abstract Number: 2581 • ACR Convergence 2023
Proteomic Signatures in Pre-Rheumatoid Arthritis Suggest Evolving Biological Pathways in Different Stages of Disease Development That May Inform Prediction and Prevention Strategies
Samir Rachid Zaim¹, Adam Savage¹, Mark Gillespie¹, Christy Bennett¹, lynne Becker¹, LauraKay Moss², Marie Feser², Jess Edison³, Ted R Mikuls⁴, Michael Holer², kevin Deane² and Xiao-Jun Li¹, ¹Allen Institute for Immunology, Seattle, WA, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³Walter Reed Military Medical Center, Bethesda, MD, ⁴Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) includes a stage of development that can be termed 'pre-RA' and defined as the presence of abnormal biomarkers and/or other features…
Abstract Number: 0962 • ACR Convergence 2023
Topological Proteomic Differences in Fibrotic and Unaffected Skin in Scleroderma
Irene Choi¹, Courtney Yu², Francesco Boin¹, Elizabeth Volkmann³, Stephanie Stanford² and Nunzio Bottini⁴, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of California San Diego, San Diego, CA, ³University of California Los Angeles, Los Angeles, CA, ⁴University of California, San Francisco, CA
Background/Purpose: Scleroderma (SSc) is a chronic autoimmune and rheumatic disease characterized by varying levels of tissue fibrosis in the skin and other internal organs. It…
Abstract Number: 2601 • ACR Convergence 2023
Identification of Giant Cell Arteritis Using Plasma Proteome Profiles Integrated with Machine Learning
kevin cunningham¹, Jaeyun Sung², Benjamin Hur², VINOD GUPTA², Matthew Koster², Cornelia M. Weyand³, David Cuthbertson⁴, Nader Khalidi⁵, Curry Koening⁶, Carol Langford⁷, Carol McAlear⁸, Paul Monach⁹, Larry Moreland¹⁰, Christian Pagnoux¹¹, Rennie Rhee⁸, Philip Seo¹², Peter Merkel⁸ and Kenneth Warrington², ¹University of Minnesota, Minneapolis, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic School of Medicine and Stanford University, Rochester, MN, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Texas Dell Medical School, Austin, TX, ⁷Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰University of Colorado, Denver, CO, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Johns Hopkins University, Baltimore, MD
Background/Purpose: The availability of diagnostic laboratory tests and specific biomarkers of disease activity for giant cell arteritis (GCA) remains an area of unmet need. The…
Abstract Number: 1608 • ACR Convergence 2023
Plasma Proteomic Profiling in Antiphospholipid Antibody-positive Patients with Different Clinical Phenotypes: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
Ayesha Butt¹, Rolando Garcia Milian¹, George Goshua¹, Sean Gu¹, Eugenia Chock², Valentina Restrepo¹, John Hwa¹, Hyung Chun¹, H Michael Belmont³, Kello Nina⁴, D. Ware Branch⁵, Michelle Petri⁶, Jason Knight⁷, Rohan Willis⁸, Maria Laura Bertolaccini⁹, Doruk Erkan¹⁰, Alfred lee¹, Anish Sharda¹ and Alexander Pine¹¹, ¹Yale School of Medicine, New Haven, CT, ²Yale School of Medicine, Greenwich, CT, ³NYU School of Medicine, New York, NY, ⁴Northwell Health, Brooklyn, NY, ⁵University of Utah, Salt Lake City, UT, ⁶Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁷University of Michigan, Ann Arbor, MI, ⁸University of Texas Medical Branch, Galveston, TX, ⁹King's College London, London, United Kingdom, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹VA Connecticut/Yale School of Medicine, West Haven, CT
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with thrombotic and obstetric complications arising via a model of immunothrombosis. Patients may present with a spectrum…
Abstract Number: 1633 • ACR Convergence 2023
Dose Dependent Modulation of a B Cell Protein Signature by Ianalumab in Patients with Sjögren’s Disease
Stephanie Finzel¹, Andrea Grioni², Benjamin A Fisher³, Athena S Papas⁴, Alexandre Avrameas², Danny Tuckwell², Jonas Zierer², Celine Rauld², Valeria De Luca², Enrico Ferrero², Andre Nogueira da Costa², Rainer Hillenbrand², Isabelle Isnardi² and Wolfgang Hueber², ¹Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany, ²Novartis Pharma AG, Basel, Switzerland, ³University of Birmingham, Birmingham, United Kingdom, ⁴Division of Oral Medicine, Tufts School of Dental Medicine, Boston, MA
Background/Purpose: Ianalumab (VAY736) is an afuscosylated monoclonal antibody targeting the B cell activating factor receptor (BAFFR) that depletes B cells via enhanced antibody dependent cellular…
Abstract Number: 1637 • ACR Convergence 2023
IgG-Fc-N-Sialylation and -Galactosylation in Primary Sjögren’s Syndrome (Pss) in Its Potential as Marker of Disease State and Disease Activity
Helena Achten¹, Liselotte Deroo², Kristel De Boeck³, Matthias Jarlborg¹, Tine Decruy¹, Joke Deprez¹, Emilie Dumas¹, Dirk Elewaut⁴ and isabelle peene⁵, ¹Ghent University, Ghent, Belgium, ²Ghent University, Gent, Belgium, ³Ghent University Hospital, Ghent, Belgium, ⁴Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁵University Hospital Ghent, Ghent, Belgium
Background/Purpose: Loss of galactose and sialic acid structures attached to the IgG-Fc-fragment switches the antibody effector function from anti-inflammatory to pro-inflammatory1. This study investigated the…

« Previous Page
1
…
4
5
6
7
8
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].